Publication | Closed Access

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours

MedicineImmunologyAdvanced Solid TumoursImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyCancer ResearchJapanese Patients